| Project/Area Number |
09671308
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Shimane Medical University |
|---|
Principal Investigator |
KUBOTA Hirofumi Shimane Medical University, Second Department of Surgery, Assistant Professor, 医学部, 講師 (00205147)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
HISHIKAWA Yoshitaka Shimane Medical University, Second Department of Surgery, Assistant Professor, 医学部, 助手 (60304276)
田原 英樹 島根医科大学, 医学部, 助手 (90252931)
|
|---|
| Project Period (FY) |
1997 – 1998
|
| Project Status |
Completed (Fiscal Year 1998)
|
| Budget Amount *help |
¥1,100,000 (Direct Cost: ¥1,100,000)
Fiscal Year 1998: ¥500,000 (Direct Cost: ¥500,000)
Fiscal Year 1997: ¥600,000 (Direct Cost: ¥600,000)
|
|---|
| Keywords | nude mice / gastric cancer / antiangiogenic factor |
|---|
| Research Abstract |
Human esophageal squamous cell careinoma starains, ES63 and ES80 implanted subcutaneously (s.C.) in nude mice were used to evaluate antiangiogenic effect of thalidomide (200 mg/kg/day) after daily ravage or intrapeeritoneal (i.p.) ininistaration. Tumor size was measured and assessment of microvessel density (MVD) was performed with GSL-1 (Grzffoniasimpliczfolia
lectin I) histochemically. Characteiizations of angiogenic factors, vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF) and thymicine phosphorylase (dThdPase) in ES63 and ESBO tumors were done by immunohistochemical staining and reverse transcription-polymerase chain reaction (RT-PCR).
ES63 strongly expressed three angiogenic factors but ES8O showed moderate expression of dThdPase and only weak or no expression of VEGF and bFGF at protein and mRNA levels. In ES63, i.p. injection of thalidomide produced significant inhibition of tumor growth, but there was no effect following gastric gavage. Also significantly lower MVD was encountered in the ip. thalidomide group. However. in ESSO tumor strain, thalidomide had no antiangiogenic effect following either i.p. or oral administration.
These data indicate that thalidomide exerts antiangiogenic effect on solid tumor following i.p. administration. Thalidomide might be one of the hopeful antiangiogenic drags for soild tumors.
|
